Truist notes that uniQure (QURE) has shared that based on recent pre-BLA mtg, the FDA is unlikely to approve AMT-130 with current data package. Based on the firm’s prior conversations with thought leaders in Huntington’s disease, this may, at least in part, be related to the use of ENROLL-HD natural history as matched control. This is a unique issue for uniQure with no read-throughs to PTC Therapeutics (PTCT) and Wave Life Sciences’ (WVE) HD programs, in Truit’s view.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure falls -50.2%
- Midday Fly By: AWS in deal with OpenAI, Kimberly-Clark to buy Kenvue
- FDA’s ‘surprising’ uniQure reversal drags down Biohaven
- Optimistic Buy Rating for uniQure Amid Promising AMT-130 Data and Regulatory Prospects
- FDA’s uniQure reversal unlikely to impact Regenxbio’s programs, says Stifel